OncoSil Medical (ASX:OSL) Selling, General, & Admin. Expense: A$7.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:OSL OncoSil Medical Ltd ASX:OSL
48 GF Score
Price A$1.38
GF Value A$2.90
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is OncoSil Medical Selling, General, & Admin. Expense?

OncoSil Medical ASX:OSL -1.79% 48 Selling, General, & Admin. Expense is A$7.00 Mil as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.90 (Possible Value Trap). The stock has 4 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. OncoSil Medical's selling, general, & admin. expense for the six months ended in Dec. 2025 was A$3.09 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$7.00 Mil.


OncoSil Medical  (ASX:OSL) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


OncoSil Medical Selling, General, & Admin. Expense Related Terms


OncoSil Medical Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for OncoSil Medical's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSil Medical Selling, General, & Admin. Expense Chart

OncoSil Medical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.65 7.17 6.69 6.63 7.83

OncoSil Medical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.17 3.46 3.92 3.91 3.09

ASX:OSL vs ABT, SYK, MDT: Selling, General, & Admin. Expense Comparison

For the Medical Devices subindustry, OncoSil Medical's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSil Medical Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where OncoSil Medical's Selling, General, & Admin. Expense falls into.


ASX:OSL
48GF Score
OncoSil Medical Ltd ASX:OSL
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoSil Medical Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$7.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of A$7.00 Mil mean?
OncoSil Medical (ASX:OSL) has a Selling, General, & Admin. Expense of A$7.00 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on OncoSil Medical and its competitors.
Is OncoSil Medical's Selling, General, & Admin. Expense too high?
OncoSil Medical's current Selling, General, & Admin. Expense is A$7.00 Mil. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Selling, General, & Admin. Expense compare to ABT and SYK?
OncoSil Medical's Selling, General, & Admin. Expense of A$7.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on OncoSil Medical and its competitors. OncoSil Medical's current Selling, General, & Admin. Expense is A$7.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current Selling, General, & Admin. Expense is A$7.00 Mil. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Selling, General, & Admin. Expense is A$7.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoSil Medical (ASX:OSL) Overvalued in 2026?

Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued. The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90. GuruFocus considers OncoSil Medical to be Possible Value Trap.

Key valuation signals for ASX:OSL:

  • Selling, General, & Admin. Expense: A$7.00 Mil
  • GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
  • GF Score™: 48/100 with 4 warning signs

No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


OncoSil Medical Business Description

Address 7 Eden Park Drive, Level 5, Macquarie Park, Sydney, NSW, AUS, 2113
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score

Get the complete analysis for ASX:OSL

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.38
Price
A$2.90
GF Value